Pregabalin
Ischemia
Karolinska InstitutetSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Ischemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Xijing Hospital | Phase 4 | BBB |
UROKINASE-TYPE PLASMINOGEN ACTIVATOR medac GmbH | Phase 3 | BB |
Vorapaxar Merck Sharp & Dohme LLC | Phase 3 | B |
Tocilizumab Zhujiang Hospital | Phase 3 | B |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Zhujiang Hospital | Phase 3 | B |
View all 10 →
Same molecule, other indications
Pregabalin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →